The global tumor ablation market size was valued at USD 1,210 million in 2021. It is anticipated to generate USD 3,889 million by 2030, growing at a CAGR of 13.85% during the forecast period (2022–2030). Ablation is a needle-based procedure for removing malignant or unhealthy tissue. Tumor ablation is a minimally invasive surgical procedure for the treatment of solid tumors. Unique probes are used to "burn" or "freeze" tumors without surgery. The needle probe is guided and placed into cancer using computed tomography (CT), ultrasound, or magnetic resonance imaging (MRI).
Compared to open surgery, this type of therapy requires less anesthesia, causes minor trauma and discomfort, and patients stay in the hospital for shorter periods and recover faster. The dead tumor tissue diminishes and is replaced by scar tissue over time after tumor ablation, and it may eventually disappear. Ablation can decrease tumors, which can prolong life, relieve discomfort, and even cure cancer in rare situations.
Get more information on this report Download Sample Report
Ablation is a procedure that kills a tumor in the liver without removing it. When a patient has a few small tumors and surgery is not an option, this approach can be helpful. Furthermore, patients receiving such treatment are less likely to require hospitalization, resulting in a higher likelihood of ablation system adoption among individuals. An increasing prevalence of breast cancer, colon cancer, prostate cancer, and lung cancer is expected to increase demand for ablation technologies to treat kidney, soft tissue, liver, and bone tumors.
As the leading cause of death, cancer is considered a universal health problem. According to the National Cancer Institute, approximately 1,806,590 new cancer cases were diagnosed in the United States in 2020. Furthermore, the American Cancer Society added that 1.8 million new malignancies were diagnosed in the United States in 2020. Additionally, the increasing worldwide prevalence of cancer is expected to increase the demand for tumor ablation devices. According to the World Health Organization, about 3.7 million new cancer cases are reported in Europe each year. As a result, the rising global prevalence of cancer is expected to provide considerable growth prospects for market players over the forecast period.
Ablation device improvements have improved accuracy, mobility, and cost-effectiveness, prompting market participants to launch and upgrade new devices on a regular basis. Some of the significant technological breakthroughs in the industry are irreversible electroporation, HIFU, cryoablation, and image-guided equipment. Larger and more complex cancers in various organs can now be treated thanks to advancements in existing technology and the advent of innovative ablation procedures. In addition, advances in intraprocedural imaging aim to improve treatment quality and reduce complications. Intraprocedural imaging advancements have improved treatment preparation and provided a precise assessment of the ablation zone during treatment.
To maintain a solid position in the industry, various market participants are developing and marketing innovative ablation devices. The FDA has given regulatory approval to several ablation systems. For example, Ethicon, a Johnson & Johnson subsidiary, earned FDA breakthrough device designation for microwave technology in August 2020. In addition, Sonacare Medical got FDA approval for its HIFU prostate tissue ablation device in January 2017. Such initiatives by various market players are expected to generate widespread product demand, resulting in market expansion.
The financial load on the healthcare system is growing as the aging population grows. According to the Population Reference Bureau, the number of individuals aged 65 and up in the United States will nearly quadruple by 2060, from 52 million in 2018. As the population of the elderly grows, so will the demand for ablation devices for tumor therapy, boosting the market. Furthermore, disorders like cancer and diabetes are pervasive among the elderly, who are more prone to experience complications following chemotherapy or surgical treatment.
In addition, market growth is likely to be aided by a combination of decreased immune system activity in the senior population and higher co-morbidities. Elderly patients with liver cancer have a poorer liver function and more co-morbidities, and they frequently seek minimally invasive operations for a speedier recovery, which drives the tumor ablation market. As the body's primary systems deteriorate with age, the geriatric population is the primary target demographic for noninvasive ablation techniques. As a result, the expanding senior population is expected to drive demand for tumor ablation systems during the projected period.
Several malignant and benign tumors can be treated with minimally invasive procedures to minimize the discomfort, pain, and recovery time associated with traditional surgery. Such procedures may only involve a local anesthetic and may be a viable alternative for many people who are not surgical candidates. Many of these procedures are performed on an outpatient basis, with patients typically returning home the same day, increasing the demand for ablation procedures.
Furthermore, as compared to open surgery approaches, minimally invasive surgeries offer several advantages, which are expected to drive the tumor ablation market forward. Faster healing, smaller incisions, less scarring and pain, better precision, and shorter hospital stays are advantages of minimally invasive surgery. Since ultrasound, radiofrequency ablation, and laser ablation are minimally invasive procedures, the tumor ablation market is likely to grow over the forecast period due to increased demand for minimally invasive surgery.
Ablation therapy of tumors has recently emerged as a potential treatment option for various cancers that affect solid organs. Complications can become more common as the number of procedures performed grows. Bleeding and damage to the target organ are the two problems of ablation that occur most frequently. On the other hand, these difficulties are arranged according to their risks. The complications that can arise from these surgical procedures can slow the expansion of the market.
According to the FDA, ablation devices are classified as medical devices in Class II and III. These classes necessitate more supervision and control. Class II devices require premarket notification, and class III devices require regulatory approval (PMA). Labeling requirements, manufacturing plant-established registration, medical device listing, quality systems control, and medical device reporting are the basic permissions necessary (MDR).
The FDA's Center for Devices and Radiological Health (CDRH) oversees the framework and standards for imported devices sold in the United States, including production, labeling, packaging, and storage. Companies must comply with many regulatory standards and keep appropriate documentation to gain approval and clearance. Medical gadgets cannot be sold unless specific requirements are met. If there are any flaws or complaints, the product is taken off the market.
The global tumor ablation market share is categorized based on technology, treatment, and application.
Based on the technology used, radiofrequency ablation and cryoablation are the major shareholders in the global tumor ablation market. The market revenue of radiofrequency ablation and cryoablation was valued at USD 357 million and USD 255 million, respectively, in 2021. The decreased need for opioids or other analgesics, quick recovery, and long-lasting and better pain relief than steroid injections drive the market for radiofrequency ablation. Cryoablation creates a ball of ice at a negative temperature using liquid nitrogen. Nitrogen is pumped by a probe placed into tumor tissue which destroys liver, kidney, lung, prostate, and bone tumor cells. Cryoablation patients are recovered faster with minor side effects, smaller and less scaring, less postoperative discomfort, shorter hospital stays, and less need for pain killers. This will help segment growth. The global market for radiofrequency ablation is projected to generate USD 1,089 million in 2030, growing at a CAGR of 13.2%.
Based on the treatment done, the tumor ablation market is segmented into surgical ablation, laparoscopic ablation, and percutaneous ablation. Percutaneous ablation is the highest market shareholder and is projected to generate USD 1,453 million at a CAGR of 14.25% by 2030. Percutaneous ablation is a tumor removal procedure in which the radiofrequency probe is placed through a small incision. This method destroys target tumor cells. This segment is driven by factors like shorter surgeries, faster recoveries, and higher patient comfort.
Application-wise, prostate cancer is the largest market holder. The global market for prostate cancer is projected to generate USD 892 million at a CAGR of 14.15% by 2030. Prostate cancer elimination uses focal therapy. MRI-guided laser ablation destroys tiny cancers and protects normal tissue. This procedure has a low risk of post-surgery incontinence and impotence, quick recovery, no need for local anesthetic, and few side effects, further driving the market. Lung cancer is anticipated to be the second-largest market holder. This category is growing because of the rising incidence of lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC).
Based on region, the global tumor ablation market share is segmented into North America, Europe, Asia-Pacific, Latin America, and Middle-East Africa.
Regional Growth Insights Request Sample Pages
North America is anticipated to hold the largest market share of USD 1,063 million by 2030 at a CAGR of 13.3% during the forecast period. Government support for excellent healthcare, high disposable income, reimbursement availability, and the increasing prevalence of cancer in the United States and Canada are all factors contributing to its expansion. United States owns a significant portion of the tumor ablation market, with a market value of USD 299 million in 2021. Furthermore, the rising senior population and rising obesity rates have increased cancer risk, which is expected to drive the adoption of cancer therapy and diagnosis.
Europe is the second-largest contributor to the tumor ablation market and is anticipated to hold a market share of USD 1,038 million by 2030 at a CAGR of 13%. Public funding in Europe's healthcare system has boosted the market. The growing geriatric population and government cancer support have expanded the market. Germany and UK have more market revenue compared to France. The market revenue of Germany and the UK were valued at USD 68 million and USD 65 million, respectively, in 2021.
The tumor ablation market in the Asia-Pacific is expected to witness exponential growth. The Asia-Pacific market is predicted to increase due to better healthcare infrastructure and government initiatives. Economic improvements in India and China are likely to boost the market growth. Thus, collaborative partnerships and bilateral agreements with companies in this region create growth opportunities. Japan and China are growing their market gradually, with market revenue of USD 78 million and USD 67 million, respectively, in 2021.
Latin America and the Middle East and Africa have the lowest market. Increased geriatric population, cancer prevalence, minimally invasive diagnostics, and public-private partnerships will boost the tumor ablation business. In the Middle East and Africa, Saudi Arabia is the major contributor, while in Latin America, Brazil is the primary market shareholder.
The presence of local and foreign firms working in tumor ablation-based instruments characterizes the global market. The existence of several enterprises involved in the production of a significant number of products offered under trademarked brand names defines the market. Product design, technology kind, operational efficiency, and overall price are all variables that companies compete on in the market. Legal implications, data security, reimbursement systems, corporate compliance procedures, responsible data collecting and usage, and product development speed are all challenges that companies entering the market must solve. High competition from low-cost products made by medium and small businesses is predicted to lead to intense competitive rivalry and a drop in overall product price.
|Market Size||USD in Billion By 2030|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
|Segments Covered||by Technology (Microwave Ablation), Treatment (Surgical, Laparoscopic), Application (Kidney Cancer, Liver Cancer)|
|Geographies Covered||North America, Europe, Asia-Pacific, LAME and Rest of the World|
|Key Companies Profiled/Vendors||Medtronic, Johnson & Johnson (Ethicon Inc.), Angiodynamics, Galil Medical Inc., Mermaid Medical, EDAP TMS, Sonacare Medical, Theraclion, Chongqing Haifu Medical Technology Co. Ltd, Boston Scientific Corporation, Icecure Medical, HS Hospital Service S.P.A, Healthtronics Inc, Misonix,|
|Key Market Opportunities||Rapid Growth In Healthcare It Industry Enhances Tumor Ablation Market|